The U.S. Food and Drug Administration accepted for priority review a Biologics License Application (BLA) for Merck’s 15-valent pneumococcal conjugate vaccine V114.
Affinivax Inc., a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS (Multiple Antigen Presenting System) platform, announced the closing of a $226 million Series C financing.
The U.S. Food and Drug Administration accepted for priority review Pfizer Inc.’s Biologics License Application (BLA) for the 20-valent pneumococcal conjugate vaccine (20vPnC) candidate, as submitted for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults ages 18 years and older.
Merck reported results from two more Phase III trials of the company’s 15-valent pneumococcal conjugate vaccine V114, with plans to apply for approval to regulatory agencies before the end of 2020, beginning with the U.S. Food and Drug Administration.
Merck reported positive results regarding the safety, tolerability and immunogenicity in two Phase III studies for V114, the company’s investigational 15-valent pneumococcal conjugate vaccine.